These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 7882335)
1. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335 [TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Fueyo J; Gomez-Manzano C; Yung WK; Clayman GL; Liu TJ; Bruner J; Levin VA; Kyritsis AP Oncogene; 1996 Jan; 12(1):103-10. PubMed ID: 8552379 [TBL] [Abstract][Full Text] [Related]
3. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755 [TBL] [Abstract][Full Text] [Related]
4. Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation. Hama S; Sadatomo T; Yoshioka H; Kurisu K; Tahara E; Naruse I; Heike Y; Saijo N Anticancer Res; 1997; 17(3C):1933-8. PubMed ID: 9216647 [TBL] [Abstract][Full Text] [Related]
6. Loss of P16INK4 expression is frequent in high grade gliomas. Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764 [TBL] [Abstract][Full Text] [Related]
7. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773 [TBL] [Abstract][Full Text] [Related]
8. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Brenner AJ; Aldaz CM Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417 [TBL] [Abstract][Full Text] [Related]
9. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630 [TBL] [Abstract][Full Text] [Related]
10. Mutation rate of the CDKN2 gene in malignant gliomas. Giani C; Finocchiaro G Cancer Res; 1994 Dec; 54(24):6338-9. PubMed ID: 7987825 [TBL] [Abstract][Full Text] [Related]
11. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391 [TBL] [Abstract][Full Text] [Related]
13. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Herman JG; Merlo A; Mao L; Lapidus RG; Issa JP; Davidson NE; Sidransky D; Baylin SB Cancer Res; 1995 Oct; 55(20):4525-30. PubMed ID: 7553621 [TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506 [TBL] [Abstract][Full Text] [Related]
15. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Pollock PM; Pearson JV; Hayward NK Genes Chromosomes Cancer; 1996 Feb; 15(2):77-88. PubMed ID: 8834170 [TBL] [Abstract][Full Text] [Related]
16. Increased p16 levels correlate with pRb alterations in human urothelial cells. Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Geradts J; Kratzke RA; Niehans GA; Lincoln CE Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382 [TBL] [Abstract][Full Text] [Related]
18. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Luca M; Xie S; Gutman M; Huang S; Bar-Eli M Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563 [TBL] [Abstract][Full Text] [Related]
19. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443 [TBL] [Abstract][Full Text] [Related]
20. Deletion of p16INK4A/CDKN2 and p15INK4B in human somatic cell hybrids and hybrid-derived tumors. Kuerbitz SJ; Malandro J; Compitello N; Baylin SB; Graff JR Cell Growth Differ; 1999 Jan; 10(1):27-33. PubMed ID: 9950215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]